Scolaris Content Display Scolaris Content Display

Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer

This is not the most recent version

view the current version 12 December 2012

Appendices

Appendix 1. Search strategy for MEDLINE

  1. "randomi*ed controlled trial".pt.

  2. controlled clinical trial.pt.

  3. "randomi*ed".ab.

  4. placebo.ab.

  5. drug therapy.fs.

  6. randomly.ab.

  7. trial.ab.

  8. groups.ab.

  9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8

  10. humans.sh.

  11. 9 and 10

  12. (cervi* adj3 canc*).ab,ti.

  13. (cervi* adj3 carcinoma*).ab,ti.

  14. exp uterine cervical neoplasms/

  15. 12 or 13 or 14

  16. drug therapy.fs.

  17. chemotherapy.ab,ti.

  18. 16 or 17

  19. hysterectomy.ab,ti.

  20. surgery.ab,ti.

  21. 19 or 20

  22. 11 and 15 and 18 and 21

Appendix 2. Search Strategy for CENTRAL  

#1        MeSH descriptor Uterine Cervical Neoplasms explode all trees
#2        (cervi* near canc*):ti,ab,kw
#3        (cervi* near carcinoma*):ti,ab,kw
#4        (cervi* near neoplasm*):ti,ab,kw
#5        (cervi* near tumour*):ti,ab,kw
#6        (cervi* near tumor*):ti,ab,kw
#7        (#1 OR #2 OR #3 OR #4 OR #5 OR #6)
#8        MeSH descriptor Drug Therapy explode all trees
#9        (chemotherapy):ti,ab,kw
#10      (#8 OR #9)
#11      (hysterectomy):ti,ab,kw
#12      (surgery):ti,ab,kw
#13      (#11 OR #12)
#14      (#7 AND #10 AND #13)

Appendix 3. Search strategy for LILACS

(Tw estud$ OR Tw clinic$ OR AB grupo$ OR CT COMPARATIVE STUDY OR Tw placebo$ OR Tw random$ OR Ti compara$ OR Ti tratamiento OR Tw control$ OR MH/dt) AND NOT ((CT ANIMALS FEMALE OR CT ANIMALS MALE OR CT CATS OR CT CATTLE OR CT CHICK EMBRYO OR CT DOGS OR CT GUINEA PIGS OR CT IN VITRO OR CT MICE OR CT RABBITS OR CT RATS) OR (MH Prevalence OR MH Practice Guidelines OR MH Diagnosis, Differential OR MH Cross‐Sectional Studies OR MH predictive value of tests) OR (Ti clinical AND case OR Ti updat$ OR Ti Epidemiol$ OR Ti clinical$ AND case$ OR Ti caso AND clinico OR Ti review OR Ti diagno$ AND treatment OR Ti descrip$ OR Ti consenso OR Ti caso$ AND control$ OR Ti analisis AND critico) OR (AB retrospectiv$ and stud$ OR AB estudio AND retrospectivo OR AB revis$ AND ficha$ OR AB revision AND bibliograf$ OR AB estud$ AND descript$ OR AB presenta AND caso OR AB describe AND caso OR AB serie AND clinica OR AB puesta AND al AND dia OR AB tratamiento AND diagnostic$ AND revis$ OR AB experien$ AND caso$ OR AB analisis AND critico) OR (PT case reports OR PT review) AND NOT (Tw estud$ OR AB grupo$ OR Tw control$ OR Tw random$)) and (Mh uterine cervical neoplasms/) or (tw Cerv$ AND (Tw carcinoma$ or Tw cancer$))  and (Mh Drug therapy/) or (Tw chemotherapy) or (Tw surg$)

Table 1. Table 01 Risk of Bias Tool

Sequence generation.

Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.

Was the allocation sequence adequately generated?

Allocation concealment.

Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment.

Was allocation adequately concealed?

Blinding of participants, personnel and outcome assessorsAssessments should be made for each main outcome (or class of outcomes). 

Describe all measures used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.

Was knowledge of the allocated intervention adequately prevented during the study?

Incomplete outcome dataAssessments should be made for each main outcome (or class of outcomes). 

Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition/exclusions where reported, and any re‐inclusions in analyses performed by the review authors.

Were incomplete outcome data adequately addressed?

Selective outcome reporting.

State how the possibility of selective outcome reporting was examined by the review authors, and what was found.

Are reports of the study free of suggestion of selective outcome reporting?

Other sources of bias.

State any important concerns about bias not addressed in the other domains in the tool.

If particular questions/entries were pre‐specified in the review’s protocol, responses should be provided for each question/entry.

Was the study apparently free of other problems that could put it at a high risk of bias?

Figures and Tables -
Table 1. Table 01 Risk of Bias Tool
Navigate to table in Protocol